The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

Chronic kidney disease is a common complication for ... The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation compared with baseline, onset of persistent ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Find out if it's safe to drink alcohol during your Ozempic treatment, whether alcohol raises the risk of any sides effects, and more.

Alembic is introducing diltiazem hydrochloride extended-release capsules 120 mg, 180 mg and 240 mg, which are the generic of ...

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...